Type 2 Inflammation - Severe Asthma and Co-Morbidities

Price: FREE for members and non-members
Session recorded on July 23, 2019
Speaker: Bradley, Chipps, MD
Viewers can earn credit by completing the post test questions.

This activity aims to provide both the appropriate background information and the prescribing guidance based in published clinical evidence, required to improve the competence of learner's ability to choose the best medical therapy for patients with Type 2 Inflammation.

This program is a collaboration between the American College of Allergy, Asthma and Immunology and the Allergy and Asthma Network.

There is no commercial support for this activity.
 

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


 

Target Audience

Primary Care Providers

Learning Objectives

After viewing the video recording learners should be able to:

  • Determine the response predictors for the 5 monoclonal antibodies for asthma
  • Examine the specific criteria for monoclonal antibodies
  • Explore the limited intervention for low T2 asthma


 

Additional information
Disclosure: 

Disclosure:

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewers, and other individuals in a position to control or influence the content of an activity must disclose all financial relationships with any commercial interest that have occurred within the past 12 months. All identified conflicts of interest must be resolved and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure be provided to the learners prior to the start of the activity. Individuals with no financial relationships to disclose must also inform the learners that no financial relationships exist. Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials. Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

 

All identified conflicts of interest have been resolved.

Michael Blaiss, MD, Planner
Consultant/Consulting fee: ALK, DBV, Hycor, Merck, Pfizer, Sanofi, Stallergenes Greer, PMD Healthcare
Bradley Chipps, MD Speaker
Consultant/Speaker: Astra Zeneca, Circassia, Genentech, Novartis, Regeneron, Sanofi, Teva

 

 

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
07/23/2019
Course expires: 
10/31/2021
Rating: 
0

Accreditation
The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

Designation
The American College of Allergy, Asthma and Immunology (ACAAI) designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Please login or create an account to take this course.